Accessible healthcare

Accessible healthcare

As one of the leading generic manufacturers, we deliver on our objective, which is to produce high-quality, state-of-the-art and accessible generic medicines for the most common diseases of our time. More than 100 million patients from all over the world use our medicines every day.

Patient-tailored product portfolio

Our product portfolio – more than half of which consists of cardiovascular medicines – follows the guidelines of the 2030 Agenda for Sustainable Development laid down by United Nations. Physicians can choose from many generic medicines that combine several active ingredients and prescribe the most suitable therapy for each patient for the best treatment outcome.

Accessible medicines

As one of the leading generic manufacturers, we deliver on our objective, which is to produce high-quality, state-of-the-art and accessible medicines for the most common diseases of our time. More than 100 million patients from all over the world use our medicines every day.

R&D and a culture of innovation

Our continuous investments into knowledge and state-of-the-art equipment are key to maintaining our competitive edge over generic producers. We extend our key therapeutic areas by constantly developing and obtaining marketing authorisations for new products. We introduce state-of-the-art technologies to ensure undisturbed supply, highest quality and affordable products. We develop innovative products in complex pharmaceutical forms with added value for patients.

Efficient registration procedures

Efficient development process and registration procedures are our competitive advantages. They allow us to offer high-quality, safe and effective medicines to patients in the shortest time possible after patent protection expires and after obtaining the relevant marketing authorisations.

Expert support for healthcare professionals

Healthcare professionals are an important link between us and patients – we provide them with the latest, clear, accurate and balanced information on therapeutic ares, therapies and our products, so that they can make the best possible decision regarding therapy for their patients.

Raising awareness about healthy lifestyles and identification of widespread diseases

Our mission is living a healthy life; to implement it we carry out many activities for our employees and the lay public that highlight the problems related to healthcare and the importance of risk factor identification for individual chronic diseases, particularly cardiovascular and mental diseases, and promote activities that contribute to a healthy lifestyle.

Uninterrupted supply of medicines

We base the principles of our social responsibility on providing undisturbed supply; this helps us maintain the reputation of being a reliable partner in the eyes of patients and direct customers.

Goals by 2030

Improving our product accessibility through annual sales volume growth: 5% (on average annually)

Improving our product accessibility through annual sales volume growth for patients with chronic non-communicable diseases (cardiovascular diseases and diabetes) and direct contribution to sustainable development goals from the 2030 Agenda (UN): 3% (on average annually)

Improving the accessibility of our combination medicines for treating cardiovascular diseases, diabetes, and pain through annual sales volume growth of combination medicines: 5% (on average annually)

Direct customer satisfaction, measured by the CSI index: > 80%

Annual revenue allocated to R&D: 10 %

Krka around the world